Alacrita is pleased to announce the appointment of Peter G. Traber, MD, as Partner in its Waltham, MA office. Peter is a distinguished scientist and gastroenterologist/hepatologist with over 30 years of experience. He will support clients on a range of drug development, clinical, and strategic challenges, with a particular focus on liver and other organ fibrosis, NASH, and GI pharma consulting.

Peter brings extensive medical leadership experience and deep expertise in fibrosis, hepatology, and gastroenterology. Most recently, he led Galectin Therapeutics as CEO and CMO where he advanced a galectin-3 inhibitor, a putative antifibrotic drug, from discovery through development to a phase 3-ready program in NASH cirrhosis and built a pipeline of other indications for the drug. Prior to this, he served as Senior Vice President and CMO at GlaxoSmithKline overseeing a broad range of therapeutic areas and drug development activities.

In academic medicine, Peter served as Chief of Gastroenterology, Chairman of Medicine and CEO of the University of Pennsylvania School of Medicine and Health System. During his tenure there Peter led a basic science laboratory program that made fundamental discoveries in liver and intestinal biology. Peter also served as President and CEO of Baylor College of Medicine.

Peter obtained an MD degree from Wayne State University School of Medicine and his board certifications from the Feinberg School of Medicine at Northwestern. He holds a BS degree in chemical engineering from the University of Michigan and a certificate in business leadership for physicians from The Wharton School.

Dr. Traber possesses a rare breadth of expertise and vision that allows him to advise clients on solutions to some of the most complex scientific, clinical and strategic challenges they may face, both in their drug discovery and development programs and organizationally.

Rob Johnson, Managing Partner at Alacrita, said: “We could not be more pleased to welcome Peter onto the Alacrita team. He brings in a truly exceptional level of expertise, especially in antifibrotic drug development and NASH. There is no doubt our clients will benefit greatly from his vision and his work and leadership on the forefront of drug development.”

Peter Traber, Partner at Alacrita, said: “I am very excited for the new challenges Alacrita brings in biotech and pharma consulting. I truly look forward to serving the industry in this new capacity with the full scope of my knowledge gained over 30 years as a scientist, clinical researcher, and physician executive.”

More Information

Please click here for more information on Dr. Traber's consulting areas and expertise.

Peter will also be routinely publishing articles and industry insight on NASH and anti-fibrotic drug development. His first article Identifying Best Disease Indications for Anti-Fibrotic Drugs can be read here.

Case Studies

For more information on how we can assist your biotech or pharmaceutical project, please reach out.

Some additional information in one line
.custom-post-pagination {display: none;}